Can we refine strategy on HDL by new pharmacological approaches?

This content is available to Full members only
Log in or sign up for an EAS membership

John Chapman

European Atherosclerosis Society
Första Långgatan 4A
413 03 Göteborg
Sweden

Phone: +46 (0) 31 760 24 27

Organisation number: 802418-0427

Send us a message

Cookies

We use cookies. If you think that's OK, just click "Accept all". You can also choose what kind of cookies you want by clicking "Settings".

Settings Accept all

Cookies

Choose what kind of cookies to accept. Your choice will be saved for one year. You can change your settings from our Cookie Policy page.

Necessary
These cookies are not optional. They are needed for the website to function.
Statistics
In order for us to improve the website's functionality and structure, based on how the website is used.
Experience and analytics
If you refuse these cookies, some functionality, like the ability to view videos, will disappear from the website.
Marketing
By sharing your interests and behaviour as you visit our site, you increase the chance of seeing personalised content and offers.

Save Accept all

Report

There was a problem reporting this post.

Offensive Contains abusive or derogatory content

Inappropriate Contains mature or sensitive content

Misinformation Contains misleading or false information

Suspicious Contains spam, fake content or potential malware

Harassment Harassment or bullying behavior

Other

Report note

Block Member?

Please confirm you want to block this member.

You will no longer be able to:

See blocked member's posts
Mention this member in posts
Invite this member to groups
Message this member
Add this member as a connection

Please note: This action will also remove this member from your connections and send a report to the site admin. Please allow a few minutes for this process to complete.

Report

You have already reported this .